» Articles » PMID: 22723919

MicroRNA-9 As Potential Biomarker for Breast Cancer Local Recurrence and Tumor Estrogen Receptor Status

Overview
Journal PLoS One
Date 2012 Jun 23
PMID 22723919
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

MicroRNAs (miRs) are small, non-protein coding transcripts involved in many cellular functions. Many miRs have emerged as important cancer biomarkers. In the present study, we investigated whether miR levels in breast tumors are predictive of breast cancer local recurrence (LR). Sixty-eight women who were diagnosed with breast cancer at the Lombardi Comprehensive Cancer Center were included in this study. Breast cancer patients with LR and those without LR were matched on year of surgery, age at diagnosis, and type of surgery. Candidate miRs were identified by screening the expression levels of 754 human miRs using miR arrays in 16 breast tumor samples from 8 cases with LR and 8 cases without LR. Eight candidate miRs that showed significant differences between tumors with and without LR were further verified in 52 tumor samples using real-time PCR. Higher expression of miR-9 was significantly associated with breast cancer LR in all cases as well as the subset of estrogen receptor (ER) positive cases (p = 0.02). The AUCs (Area Under Curve) of receiver operating characteristic (ROC) curves of miR-9 for all tumors and ER positive tumors are 0.68 (p = 0.02) and 0.69 (p = 0.02), respectively. In ER positive cases, Kaplan-Meier analysis showed that patients with lower miR-9 levels had significantly better 10-year LR-free survival (67.9% vs 30.8%, p = 0.02). Expression levels of miR-9 and another miR candidate, miR-375, were also strongly associated with ER status (p<0.001 for both). The potential of miR-9 as a biomarker for LR warrants further investigation with larger sample size.

Citing Articles

The Role of MicroRNAs in Breast Cancer and the Challenges of Their Clinical Application.

Munoz J, Perez-Moreno P, Perez Y, Calaf G Diagnostics (Basel). 2023; 13(19).

PMID: 37835815 PMC: 10572677. DOI: 10.3390/diagnostics13193072.


Assessing the Role of MicroRNAs in Predicting Breast Cancer Recurrence-A Systematic Review.

Mkabaah L, Davey M, Lennon J, Bouz G, Miller N, Kerin M Int J Mol Sci. 2023; 24(8).

PMID: 37108278 PMC: 10138898. DOI: 10.3390/ijms24087115.


miR-205-5p Downregulation and Upregulation Characterize the Disseminated Tumor Cells in Patients with Invasive Ductal Breast Cancer.

Kalinkova L, Nikolaieva N, Smolkova B, Ciernikova S, Kajo K, Bella V Int J Mol Sci. 2022; 23(1).

PMID: 35008529 PMC: 8744876. DOI: 10.3390/ijms23010103.


Hsa-miR-3651 could serve as a novel predictor for in-breast recurrence via FRMD3.

Zellinger B, Bodenhofer U, Englander I, Kronberger C, Grambozov B, Ruznic E Breast Cancer. 2021; 29(2):274-286.

PMID: 34865205 PMC: 8885475. DOI: 10.1007/s12282-021-01308-y.


Hsa-miR-375/RASD1 Signaling May Predict Local Control in Early Breast Cancer.

Zellinger B, Bodenhofer U, Englander I, Kronberger C, Strasser P, Grambozov B Genes (Basel). 2020; 11(12).

PMID: 33255991 PMC: 7759924. DOI: 10.3390/genes11121404.


References
1.
van Dongen J, Voogd A, Fentiman I, LeGrand C, Sylvester R, Tong D . Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst. 2000; 92(14):1143-50. DOI: 10.1093/jnci/92.14.1143. View

2.
Borger J, Kemperman H, Hart A, Peterse H, van Dongen J, Bartelink H . Risk factors in breast-conservation therapy. J Clin Oncol. 1994; 12(4):653-60. DOI: 10.1200/JCO.1994.12.4.653. View

3.
Jay C, Nemunaitis J, Chen P, Fulgham P, Tong A . miRNA profiling for diagnosis and prognosis of human cancer. DNA Cell Biol. 2007; 26(5):293-300. DOI: 10.1089/dna.2006.0554. View

4.
Fisher B, Anderson S, Bryant J, Margolese R, Deutsch M, Fisher E . Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002; 347(16):1233-41. DOI: 10.1056/NEJMoa022152. View

5.
Park C, Mitsumori M, Nixon A, Recht A, Connolly J, Gelman R . Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence. J Clin Oncol. 2000; 18(8):1668-75. DOI: 10.1200/JCO.2000.18.8.1668. View